relapsed/refractory chronic lymphocytic leukemia
Showing 1 - 25 of >10,000
Relapsed/Refractory Chronic Lymphocytic Leukemia Trial in Tianjin (GNC-035)
Not yet recruiting
- Relapsed/Refractory Chronic Lymphocytic Leukemia
-
Tianjin, Tianjin, ChinaInstitute of Hematology and Blood Diseases Hospital, Chinese Aca
Jul 13, 2023
Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma Trial (Nemtabrutinib, Venetoclax,
Not yet recruiting
- Leukemia, Lymphocytic, Chronic, B-Cell
- +5 more
- Nemtabrutinib
- +2 more
- (no location specified)
Jul 21, 2023
Chronic Lymphocytic Leukemia Trial in Salt Lake City (RP-3500 in combination with Olaparib)
Recruiting
- Chronic Lymphocytic Leukemia
- RP-3500 in combination with Olaparib
-
Salt Lake City, UtahHuntsman Cancer Institute at the University of Utah
Sep 23, 2022
Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small
Recruiting
- Relapsed or Refractory CD19+ B-cell Lymphoma
- +2 more
- TBI-2001
- +2 more
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Jul 26, 2023
Chronic Lymphocytic Leukemia(CLL), Small Lymphocytic Lymphoma Trial in Hackensack (Revlimid, Azacitidine)
Terminated
- Chronic Lymphocytic Leukemia(CLL)
- Small Lymphocytic Lymphoma
-
Hackensack, New JerseyHackensack University Medical Center
Jun 24, 2022
Chronic Lymphocytic Leukemia Trial in Milano (Venetoclax, Imbruvica Oral Product)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Venetoclax
- Imbruvica Oral Product
-
Milano, MI, ItalyOspedale San Raffaele
Apr 2, 2022
Relapsed/Refractory Chronic Lymphocytic Leukemia and Relapsed/Refractory Small Lymphocytic Lymphoma Trial in Italy, United
Active, not recruiting
- Relapsed/Refractory Chronic Lymphocytic Leukemia and Relapsed/Refractory Small Lymphocytic Lymphoma
- brexucabtagene autoleucel
- +2 more
-
Phoenix, Arizona
- +21 more
Jun 2, 2022
Non-hodgkin Lymphoma, Acute Lymphoblastic Leukaemia, Chronic Lymphocytic Leukemia Trial in Tianjin (CC312)
Recruiting
- Non-hodgkin Lymphoma
- +2 more
- CC312
-
Tianjin, Tianjin, ChinaInstituteHBDH
Sep 12, 2023
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Relapsed Chronic Lymphocytic Leukemia Trial in Boston (Acalabrutinib,
Active, not recruiting
- Chronic Lymphocytic Leukemia
- +3 more
- Acalabrutinib
- +2 more
-
Boston, MassachusettsDana Farber Cancer Institute
Dec 19, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial run by the (Acalabrutinib (Arm A), Acalabrutinib (Arm B))
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Acalabrutinib (Arm A)
- Acalabrutinib (Arm B)
-
Bethesda, MarylandResearch Site
Jan 3, 2023
Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma Trial in United
Recruiting
- Relapsed Chronic Lymphocytic Leukemia
- +4 more
-
Phoenix, Arizona
- +7 more
Apr 28, 2022
Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia Trial in Cleveland (Fully human anti CD19 CAR-T
Recruiting
- Non Hodgkin Lymphoma
- +2 more
- Fully human anti CD19 CAR-T Cell Dose
- +2 more
-
Cleveland, OhioUniversity Hospitals Cleveland Medical Center, Case Comprehensiv
Oct 4, 2022
Relapsed/Refractory Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Leukemia Trial in Switzerland (Ibrutinib,
Active, not recruiting
- Relapsed/Refractory Chronic Lymphocytic Leukemia
- +2 more
-
Aarau, Switzerland
- +10 more
Mar 10, 2022
B-cell Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Charleston (Cyclophosphamide injection, Fludarabine
Not yet recruiting
- B-cell Non Hodgkin Lymphoma
- Chronic Lymphocytic Leukemia
- Cyclophosphamide injection
- +2 more
-
Charleston, South CarolinaHollings Cancer Center at Medical University of South Carolina
Jan 18, 2023
Chronic Lymphocytic Leukemia Trial in Columbus, Hermitage, Fort Worth (acalabrutinib, ACP-319)
Active, not recruiting
- Chronic Lymphocytic Leukemia
-
Columbus, Ohio
- +1 more
Jan 20, 2022
Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma Trial in India (Acalabrutinib capsule)
Active, not recruiting
- Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma
- Acalabrutinib capsule
-
Ahmedabad, India
- +12 more
Feb 2, 2023
Relapsed/Refractory Chronic Lymphocytic Leukemia, Non-hodgkin's Lymphoma Trial (cerdulatinib)
Available
- Relapsed/Refractory Chronic Lymphocytic Leukemia
- Non-hodgkin's Lymphoma
- (no location specified)
May 6, 2022
Relapsed/Refractory Chronic Lymphocytic Leukemia, Richter's Syndrome Trial in Worldwide (Epcoritamab)
Recruiting
- Relapsed/Refractory Chronic Lymphocytic Leukemia
- Richter's Syndrome
- Epcoritamab
-
Tuscaloosa, Alabama
- +22 more
Jun 15, 2022
Chronic Lymphocytic Leukemia Trial in Lebanon (BNC105P, Ibrutinib)
Completed
- Chronic Lymphocytic Leukemia
- BNC105P
- Ibrutinib
-
Lebanon, New HampshireDartmouth-Hitchcock Medical Center
Jan 3, 2023
Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia Trial
Recruiting
- Recurrent Acute Lymphoblastic Leukemia
- +15 more
- Anti-CD19/CD20/CD22 CAR T-Cells
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Nov 4, 2022
Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial (BGB-21447)
Not yet recruiting
- Relapsed Non-Hodgkin Lymphoma
- +6 more
- (no location specified)
Apr 12, 2023
Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Small
Recruiting
- Recurrent Chronic Lymphocytic Leukemia
- +4 more
- Daratumumab
- Ibrutinib
-
Jacksonville, FloridaMayo Clinic in Florida
Mar 22, 2022
Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) Trial in Beijing
Recruiting
- Relapsed or Refractory B-cell Lymphoma
- +6 more
-
Beijing, ChinaBeijing Cancer Hospital
Feb 6, 2023